This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Hexyl aminolevulinate (Cevira) for cervical high-grade squamous intraepithelial lesions. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Cancer of the cervix usually takes many years to develop, and it often follows changes to the cells in the cervix called cervical intraepithelial lesions. These do not cause any harm themselves, but may need to be removed to prevent cancer in the future.
Hexyl aminolevulinate is a chemical that, when applied to the cervix and activated by a specific type of light, is used to treat cervical intraepithelial lesions. Current treatments include surgery or laser treatment.
Hexyl aminolevulinate is currently being studied to see how well it works and whether it is safe to use. If licensed, hexyl aminolevulinate will offer a new treatment for lesions of the cervix that lead to cancer.
Subject indexing assigned by CRD
Aminolevulinic Acid; Female; Humans; Squamous Intraepithelial Lesions of the Cervix
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: email@example.com
Date abstract record published